Benzinga | Nov 11, 2021 06:08AM EST

RenovoRx Announced Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting; Study Results Validate Potential for Intra-arterial Chemotherapy Delivery for the Treatment of Pancreatic Cancer

RenovoRx, Inc. (NASDAQ:RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will be presenting an ePoster at the 2021 Pancreas Club Annual Meeting being held virtually on November 11-12, 2021.

The poster describes the RR2 Observational Registry Study, which used RenovoRx's novel therapy platform, RenovoTAMP(tm) (RenovoRx Trans-Arterial Micro-Perfusion), to deliver gemcitabine, an approved chemotherapeutic agent, intra-arterially to the pancreatic tumor. The results of this study along with the prior Phase 1 study form the foundation of RenovoRx's ongoing randomized, multi-center Phase 3 clinical trial (TIGeR-PaC) of its lead product candidate, RenovoGem(tm), for the treatment of unresectable, locally advanced pancreatic cancer (LAPC).

The Registry Study, which was designed to assess the effectiveness and feasibility of intra-arterial therapeutic treatment of patients with LAPC, validated prior radiation and treatment location as predictors of overall survival. It included 25 patients (10 treatment nave, 6 with prior chemotherapy, 8 with prior chemotherapy and radiation, and 1 that had undergone prior Whipple surgery). Patients with prior radiation treatment demonstrated increased survival benefit from RenovoTAMP (median overall survival of 23.1 months) when compared to patients with prior chemotherapy (median overall survival of 16.6 months) and treatment nave patients (median overall survival of 5.7 months). In addition, treatment via the superior mesenteric artery (SMA) delivered greatest survival benefits, with median overall survival of 31.7 months when compared with treatment via other arteries. The survival benefit for patients treated with RenovoTAMP supports the rationale underlying the potential for intra-arterial, targeted chemotherapy delivery as a treatment for LAPC.

"Standard of care for patients diagnosed with unresectable LAPC is intravenous (IV) systemic chemotherapy, which both has significant side effects and is limited in its effectiveness by the lack of visible tumor feeders to pancreatic tumors," said Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx. "Based on the results of our foundational clinical trials, intra-arterial delivery of chemotherapy via RenovoTAMP not only reduced the tolerability issues associated with systemic chemotherapy, but by targeting delivery of treatment in close proximity to the tumor and pancreatic tissue, it also demonstrated improved patient survival rate."

The details of the presentation are as follows:

Title: Treating locally advanced pancreatic cancer with a novel, dual-occlusion balloon catheter Poster Number: P108 Authors: H. Charles Li; Carter Hultman; Alexander Rosemurgy, MD; J. Augusto Bastidas, MD; Reza Malek, MD; Emmanuel Zervos, MD; Steven Goldin, MD; Peter Muscarella, MD; Charles Nutting, DO; Barish Edil, MD; Ramtin Agah, MD